Company Growth (employees)
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, US
Orexigen Therapeutics Office Locations
Orexigen Therapeutics has an office in San Diego
San Diego, US (HQ)
200 3344 N Torrey Pines Ct
Orexigen Therapeutics Data and Metrics
Orexigen Therapeutics Financial Metrics
Orexigen Therapeutics's revenue was reported to be $19.1 m in Q1, 2017
USD
Revenue (Q1, 2017) | 19.1 m |
Gross profit (Q1, 2017) | 13 m |
Gross profit margin (Q1, 2017), % | 68% |
Net income (Q1, 2017) | (69.1 m) |
EBIT (Q1, 2017) | (53.8 m) |
Market capitalization (19-Sep-2017) | 35.5 m |
Cash (31-Mar-2017) | 76.7 m |
Orexigen Therapeutics's current market capitalization is $35.5 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 3.4 m | 55.5 m | 24.5 m | 33.7 m |
Revenue growth, % | 1520% | (56%) | 38% | |
Cost of goods sold | 8 m | |||
Gross profit | 25.7 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 857 k | 30.9 m | 4.4 m | 5.2 m | 10 m | 5 m | 7.8 m | 7 m | 19.1 m |
Cost of goods sold | 1.8 m | 1.9 m | 6.2 m | ||||||
Gross profit | 6 m | 5.1 m | 13 m | ||||||
Gross profit Margin, % | 77% | 72% | 68% |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 98.1 m | 104.2 m | 155.4 m | 92.5 m |
Accounts Receivable | 2.6 m | 6.8 m | 1.1 m | |
Inventories | 1.3 m | 1.5 m | 2.3 m | 23.2 m |
Current Assets | 178.3 m | 211.3 m | 233.9 m | 224.5 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 31.1 m | 68.4 m | 75.1 m | 71.6 m | 154.3 m | 68 m | 78.2 m | 74.4 m | 76.7 m |
Accounts Receivable | 32 m | 4.5 m | 6.8 m | 4.6 m | 2.8 m | 2.9 m | 2.1 m | 6.3 m | |
Inventories | 754 k | 1.4 m | 4.9 m | 11.1 m | 15 m | 11.5 m | 24 m | 20.7 m | |
Current Assets | 139.1 m | 153.2 m | 196.4 m | 189.3 m | 251.8 m | 262.4 m | 282.7 m | 273.2 m | 158.5 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (77.7 m) | (37.5 m) | (68.7 m) | (24.5 m) |
Depreciation and Amortization | 94 k | 139 k | 223 k | 3.7 m |
Accounts Receivable | (2.5 m) | (4.3 m) | 5.7 m | |
Inventories | 205 k | (175 k) | (781 k) | 1.5 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (49.4 m) | (38.1 m) | (17.2 m) | (39.7 m) | (50.9 m) | (22.3 m) | (47.6 m) | 85 k | (69.1 m) |
Depreciation and Amortization | 46 k | 87 k | 51 k | 103 k | 157 k | 78 k | 194 k | 1.7 m | |
Accounts Receivable | (31.9 m) | (2 m) | (4.2 m) | (2 m) | 4 m | 3.9 m | 4.7 m | 6.3 m | |
Inventories | (754 k) | (158 k) | (3.7 m) | (9.8 m) | (4.1 m) | (596 k) | 618 k | 20.7 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 145 k |
Financial Leverage | -30.1 x |
